Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
Nov 02, 2015	YANCOPOULOS GEORGE Director, President Regeneron Laboratori Trans History: 628	Director, President Regeneron Laboratori	Form 4	Open market or private sale of non-derivative or derivative security	530	$563.76	584,866
Nov 02, 2015	YANCOPOULOS GEORGE Director, President Regeneron Laboratori Trans History: 628	Director, President Regeneron Laboratori	Form 4	Open market or private sale of non-derivative or derivative security	100	$562.36	585,396
Nov 02, 2015	YANCOPOULOS GEORGE Director, President Regeneron Laboratori Trans History: 628	Director, President Regeneron Laboratori	Form 4	Open market or private sale of non-derivative or derivative security	1,200	$561.75	585,496
Oct 30, 2015	YANCOPOULOS GEORGE Director, President Regeneron Laboratori Trans History: 628	Director, President Regeneron Laboratori	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	92,316	$559.08	586,696
May 12, 2020	SCHLEIFER LEONARD S Director, President & CEO Trans History: 404	Director, President & CEO	Form 4	Open market or private sale of non-derivative or derivative security	9,359	$567.57	587,261
Dec 16, 2008	YANCOPOULOS GEORGE Director, EVP, CSO, & Pres Regn Res Labs Trans History: 628	Director, EVP, CSO, & Pres Regn Res Labs	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	14,922	$16.42	588,235
Dec 31, 2003	VAGELOS P ROY Director Trans History: 742	Director	Form 5	Bona fide gift	14,786	$15.10	588,485
Dec 16, 2008	YANCOPOULOS GEORGE Director, EVP, CSO, & Pres Regn Res Labs Trans History: 628	Director, EVP, CSO, & Pres Regn Res Labs	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	26,991	$7.41	590,085
Feb 10, 2017	YANCOPOULOS GEORGE Director, President & CSO Trans History: 628	Director, President & CSO	Form 5	Other acquisition or disposition	--	--	591,348
Dec 15, 2016	YANCOPOULOS GEORGE Director, President Regeneron Laboratori Trans History: 628	Director, President Regeneron Laboratori	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	95,223	$380.09	591,348

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media